Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer Inc

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

StockNews.com

Pfizer: 4 Reasons to Buy This Stock

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca

MarketBeat

3 High-Yield Dividend Stocks to Secure Before Year-End

Dividend-paying stocks provide investors with consistent income in turbulent markets, especially as payouts grow over time. Therefore, investors might consider adding dividend stocks, Pfizer (PFE), United Parcel Service (UPS), and Enterprise Products Partners (EPD) before year-end. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Cheap Stocks With High Analyst Price Targets for 2024

Cheap stocks are worth considering now due to expected interest rate cuts, potential market rebounds, and substantial upside in growing industries. Hence, stocks like Pfizer (PFE), Micron Technology (MU), and Precision Drilling (PDS), with high analyst price targets for 2024, are smart portfolio additions now. Read on.

StockNews.com

3 High-Yield Dividend Stocks to Boost Your Portfolio in 2024

With the economy showing mixed growth signals and changing federal policies, buying high-yielding dividend stocks could be a great choice for your portfolio. Thus, investors can invest in high-yield dividend stocks Pfizer (PFE), Altria Group (MO), and VICI Properties (VICI) to boost their portfolio. Read more….

StockNews.com

3 Undervalued Healthcare Stocks With Upside Potential

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and technological advancements. So, investing in undervalued healthcare stocks with upside potential, Pfizer (PFE), Cigna Group (CI), and Centene Corp (CNC), could be a wise idea. Keep reading….

StockNews.com

3 Healthcare Stocks Leading the Fight Against Global Diseases

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in established healthcare stocks, Pfizer (PFE), Merck & Co (MRK), and AbbVie (ABBV), presents a compelling opportunity to capitalize on the sector’s landscape. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Defensive Stocks to Buy as Market Volatility Rises

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading.

StockNews.com

3 Healthcare Stocks for Long-Term Stability and Growth

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more….

StockNews.com

3 High-Yield Dividend Stocks to Buy for Steady Passive Income

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, investors could consider fundamentally sound, high dividend yield stocks Verizon Communications (VZ), Pfizer (PFE), and Enterprise Products Partners (EPD) for steady passive income. Read…

StockNews.com

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just…

StockNews.com

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

StockNews.com

3 Undervalued Healthcare Stocks With Strong Upside Potential

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

StockNews.com

3 Stocks Benefiting From the Aging Population

As the aging population drives significant opportunities for companies involved in pharmaceuticals, medical devices, and health care services, let’s not miss out on investing in quality stocks like Thermo Fisher Scientific (TMO), Medtronic (MDT), and Korn Ferry (KFY), which are poised to meet the needs of an aging demographic. Learn…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 High-Yield S&P 500 Stocks to Buy and Hold

Three high-yield S&P 500 stocks, Devon Energy, Verizon Communications, and Pfizer Inc., are poised to provide a balanced mix of income and growth, making them attractive options for long-term investors.

StockNews.com

3 Healthcare Stocks Positioned for Major Gains in 2024

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

StockNews.com

3 Must-Buy Healthcare Stocks for Defensive Investing

The healthcare sector is set for significant growth due to advancements in pharma technology, increasing demand for personalized medicines, and resilience even in economic downturns. Therefore, investors might consider buying quality pharmaceutical stocks like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV) for defensive investing. Read on.

Barchart

3 Value Stocks to Buy and Hold for Passive Income

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Dividend Stability and Growth in Pharma: Pfizer (PFE) vs. Bristol-Myers Squibb (BMY)

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

StockNews.com

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

StockNews.com

Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

StockNews.com

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

Pfizer (PFE): Pre-Earnings Strategies

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.

StockNews.com

Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?

As Pfizer (PFE) navigates a post-pandemic world with a shifting focus away from COVID-related products, what should investors expect from this pharma giant? Let’s look at its financial metrics to know more….

StockNews.com

Pfizer Inc. (PFE) vs. Taro Pharmaceutical (TARO) - Betting on Which Pharma Stock Will Have Q4 Dominance

The pharmaceutical industry’s prospects are driven by the rising occurrence of chronic diseases coupled with the adoption of cutting-edge technology. In this context, which company among the two major industry players, Pfizer Inc. (PFE) and Taro Pharmaceutical (TARO) are going to dominate the fourth quarter? Let’s find out….

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.